Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

7.250 +0.290 (+4.17%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stocks That Hit 52-Week Lows On Friday ↗

February 18, 2022

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

February 22, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

February 11, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients

January 18, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Expert Ratings For Ocular Therapeutix ↗

November 09, 2021

Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst rating...

Via Benzinga

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

January 04, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial ↗

December 06, 2021

Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-...

Via Benzinga

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

December 06, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences

November 15, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix Stock Gains As Court Invalidates Drug Delivery Patent From Mati ↗

November 09, 2021

Ocular Therapeutix Inc (NASDAQ:OCUL) announce...

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 09, 2021

Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency...

Via Benzinga

Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

November 09, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix: Q3 Earnings Insights ↗

November 08, 2021

Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update

November 08, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®

November 05, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021

November 01, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results

October 29, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting

October 28, 2021

From Ocular Therapeutix

Via Business Wire

What 5 Analyst Ratings Have To Say About Ocular Therapeutix ↗

October 25, 2021

Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst ratings...

Via Benzinga

How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More ↗

October 25, 2021

Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have in the cards going forward. Galera...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

October 25, 2021

Wells Fargo boosted Bank of America Corporation (NYSE:B...

Via Benzinga

55 Biggest Movers From Friday ↗

October 25, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 22, 2021

Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's stock is trading at a volume of 116.0 million...

Via Benzinga

Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump ↗

October 22, 2021

Midway through trading Friday, the Dow traded up 0.25% to 35,690.68 while the NASDAQ fell 0.46% to 15,145.78. The S&P also rose, gaining 0.02% to 4,550.53. The U.S. has the...

Via Benzinga

Topics Stocks

35 Stocks Moving In Friday's Mid-Day Session ↗

October 22, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated...

Via Benzinga

Here's Why Ocular Therapeutix Stock Is Sinking Today ↗

October 22, 2021

The company's experimental dry-eye treatment produced some disappointing clinical trial results.

Via The Motley Fool

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint

October 22, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

10 Biggest Price Target Changes For Monday ↗

October 18, 2021

Barclays reduced the price target for The Walt Disney Company (NYSE:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.